Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04761783
Other study ID # 20-043-NCP
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date May 28, 2021
Est. completion date May 2024

Study information

Verified date December 2023
Source Natera, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tumor response. The correlation between SIGNATERA™ test results and subsequent treatment decisions will be examined to compare actual treatment delivered against treatment decisions potentially impacted by SIGNATERA™ results. Treatment administered, tumor assessment results, time to progression, overall survival, physician questionnaires, and patient-reported outcomes will be collected/recorded.


Description:

Primary Objective: ● To examine the impact of SIGNATERA™ on clinical decision-making regarding continuation, discontinuation, escalation, or de-escalation of immunotherapy. Secondary Objective: ● To prospectively evaluate the utility of SIGNATERA™ as a tool to detect early evidence of response or progression in patients with advanced solid tumors receiving immune checkpoint inhibitors.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1539
Est. completion date May 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Prospective Inclusion Criteria: 1. Male or female patients 18 years of age or older at the time of signing informed consent form (ICF) 2. Any patient with documented metastatic or locally advanced, unresectable cancer of the types within the following cohorts: 1. Melanoma 2. Non-small cell lung cancer 3. Colorectal cancer 3. Patients must be clinically eligible and planned to receive therapy with an anti-neoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4, or anti-PD-L1: 1. Pembrolizumab (Keytruda) 2. Nivolumab (Opdivo) 3. Ipilimumab (Yervoy) 4. Durvalumab (Imfinzi) 5. Cemiplimab (Libtayo) 6. Atezolizumab (Tecentriq) 7. Avelumab (Bavencio) 4. Patients must have measurable disease according to RECIST criteria, and at least one lesion that can be accurately measured in at least one dimension as >10 mm. 5. Patients must be able to follow study visit schedule and willing to provide up to 20 mL of peripheral blood samples at the indicated time points 6. ECOG Performance status 0,1, or 2 7. Able to read, understand and provide written informed consent 8. Willing and able to comply with the study requirements 9. Selected by their HCP to receive SIGNATERA testing according to the current evidence-informed schedule as part of their routine of practice Prospective Exclusion Criteria: 1. Female patients that are pregnant 2. History of bone marrow or organ transplant 3. Medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder 4. Serious medical condition that may adversely affect ability to participate in the study 5. Has initiated Immunotherapy Control Arm Inclusion Criteria: 1. Male or female patients 18 years of age or older at the time of signing informed consent form (ICF) 2. Any patient with documented metastatic or locally advanced, unresectable cancer of the types within the following cohorts: 1. Melanoma 2. Non-small cell lung cancer 3. Colorectal cancer 3. Patients must be clinically eligible and planned to receive therapy with an anti-neoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4, or anti-PD-L1: 1. Pembrolizumab (Keytruda) 2. Nivolumab (Opdivo) 3. Ipilimumab (Yervoy) 4. Durvalumab (Imfinzi) 5. Cemiplimab (Libtayo) 6. Atezolizumab (Tecentriq) 7. Avelumab (Bavencio) 4. Patients must have measurable disease according to RECIST criteria, and at least one lesion that can be accurately measured in at least one dimension as >10 mm. 5. Patients must be able to follow study visit schedule and willing to provide up to 20 mL of peripheral blood samples at the indicated time points 6. ECOG Performance status 0,1, or 2 7. Able to read, understand and provide written informed consent 8. Willing and able to comply with the study requirements 9. Selected by their HCP to receive SIGNATERA testing according to the current evidence-informed schedule as part of their routine of practice Control Arm Exclusion Criteria: 1. Female patients that are pregnant 2. History of bone marrow or organ transplant 3. Medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder 4. Serious medical condition that may adversely affect ability to participate in the study 5. Has initiated Immunotherapy

Study Design


Locations

Country Name City State
United States Natera San Carlos California

Sponsors (1)

Lead Sponsor Collaborator
Natera, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy Percent of patients who have their immunotherapy treatment regimen changed due to post-treatment SIGNATERA ctDNA test result 2 years
Secondary To determine progression free survival according to ctDNA change Compare progression free survival, defined as the duration of time between enrollment and an increase in severity of disease as determined by patient's treating physician, between groups determined by change in ctDNA 2 years
Secondary Determine overall survival according to ctDNA change Compare overall survival, defined as the duration of time between enrollment and death for any reason, between groups determined by change in ctDNA 2 years
Secondary Determine response rate according to ctDNA change in cases with progression of disease on first or second tumor assessment and who continue treatment. Compare percentage of patients that experience partial or complete response during the study, between groups determined by change in ctDNA 2 years
Secondary To determine progression free survival according to ctDNA change in cases who achieve stable disease on first tumor assessment. Compare progression free survival between groups determined by change in ctDNA 2 years
Secondary To determine duration of response according to ctDNA change in cases who achieve partial response or complete response as best overall response. Compare duration of response, defined as the length of time from initial response to disease progression, between groups determined by change in ctDNA 2 years
Secondary To determine percentage of patients with at least 6 months of durable clinical response according to ctDNA change in patients who achieve at least partial response on best tumor assessment. Among all patients that are clinically identified to experience partial or complete response, percentage that have at least 6 months durable clinical response as determined by ctDNA change 2 years
Secondary Determine the impact of SIGNATERA on the confidence in immunotherapy treatment decisions based on the number of patients in which treating physician reports SIGNATERA made them more confident in immunotherapy treatment regimen Percent of patients whose treating physician reported that SIGNATERA result made them more confident in selected immunotherapy treatment regimen 2 years
Secondary Determine the impact of SIGNATERA in informing immunotherapy treatment decisions Percent of patients whose immunotherapy treatment regimen was changed as a result of SIGNATERA and/or whose treating physician reported that SIGNATERA result made them more confident in selected immunotherapy treatment regimen 2 years
Secondary Determine the impact of SIGNATERA on patient reported outcomes Assess patient anxiety levels and wellbeing in patients receiving SIGNATERA ctDNA test results.
Patient responses to patient reported outcome questionnaires:
EORTC QLQ-C30
Assess if SIGNATERA makes patients feel that they are receiving the right treatment and determine if patients will continue to use Signatera in the future to monitor their cancer.
2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A